Referencing lowest A8 price will result in a supply crisis

By Nho, Byung Chul | translator Kim, Jung-Ju

24.01.27 05:50:52

가나다라 0

Price of generic drugs in Korea is at mid-level among A7 countries...research report "difficult to say that Korea’s drug price is high"

Health authorities stick to the lowest listed price vs. industry requests average of the highest listed price

Health authorities and the pharma-bio industry are at an impasse over the implementation of 'A8 external reference pricing reassessments.’ Engaged in a tug-of-war, the two parties have difficulty finding common grounds.

The Ministry of Health and Welfare, the Health Insurance Review and Assessment Service, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, and the Korea Research-based Pharmaceutical Industry Association, have been meeting since the end of 2022 and have completed the 5th round of negotiations as of this month, but they have been unable to reach a consensus, with each being busy making mutual claims.

The ‘reassessment for the A8 external reference pricin

Nho, Byung Chul(sasiman@dailypharm.com)

If you want to see the full article, please JOIN US (click)